← All trials
NCT05668572
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2020
- Primary completion
- Jul 21, 2022
- Completion date
- Feb 23, 2023
- First posted
- Dec 30, 2022
- Last posted
- Dec 30, 2022
- Enrollment
- 12000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing Health Guard Biotechnology, IncLead sponsor
- Beijing Health Guard Biotechnology, IncStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.